Suppression of neu overexpression using a mini-E1A gene
US6326356A · kind A · utility
3Cited by
16References
54Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 18, 1996 |
| Grant date | Dec 4, 2001 |
| Priority date | — |
| Expiry date | Oct 18, 2016 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/10343
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to methods for the inhibition, of the gene product of the neu oncogene, p185 neu tyrosine kinase. Over-expression of the neu oncogene can lead to chemoresistance. The present invention discloses the functional domains of E1A responsible for the repression of neu-mediated transformation. Further the invention discloses methods for the novel use of mini-E1A in combination with chemotherapeutic drugs and/or tyrosine kinase inhibitors. Mini-E1A may be used in the treatment of cancer and other disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.